Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Berruezo Llacuna, Maria (1) Beule, Dieter Dr. (1) Blankenstein, Thomas Prof. Dr. (3) Blüthgen, Nils (1) Caganova, Marieta Dr. (1) Daniel, Peter Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Driesner, Madlen (1) Graf, Robin Dr. (2) Höpken, Uta Elisabeth PD Dr. (1) Janz, Martin Dr. (12) Kammertöns, Thomas Dr. (3) Keller, Lisa (1) Keller, Ulrich Dr. med. (2) Kobelt, Dennis Dr. (1) Kocks, Christine Dr. (1) Landthaler, Markus Prof. Dr. (1) Leutz, Achim Prof. Dr. (1) Lusatis, Simone (1) Menzel, Lutz Peter Dr. (1) Mertins, Philipp Dr. (1) Milek, Miha Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Popp, Oliver Dr. (1) Prigione, Alessandro Prof. Dr. (1) Rahjouei, Ali Dr. (1) Rajewsky, Klaus Prof. Dr. (1) Rehm, Armin Dr. (1) Rhein, Simone Dr. (1) Schlag, Peter M. Prof. Dr. (1) Selbach, Matthias Prof. Dr. (11) Uckert, Wolfgang Prof. Dr. (13) Willnow, Thomas Prof. Dr. (1) Wollert-Wulf, Brigitte (2) Zauber, Henrik Dr. (1) (-) Leisegang, Matthias Dr. (1) (-) Mathas, Stephan Dr. (11) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) (-) 2004 (2) 2005 (2) (-) 2006 (5) (-) 2007 (3) 2008 (5) 2009 (3) 2010 (7) 2011 (5) 2012 (4) 2013 (1) 2014 (4) 2015 (8) 2016 (4) 2017 (5) 2018 (1) 2019 (2) (-) 2020 (2) 2021 (3) 2022 (4) (-) Biology of Malignant Lymphomas (11) Genetics and Genomics of Cardiovascular Diseases (1) Mechanism-based Cancer Therapies (2) (-) Molecular Cell Biology and Gene Therapy (2) Molecular Immunology and Gene Therapy (2) 12 Results: Active Filter: Leisegang, Matthias Dr.Mathas, Stephan Dr.Biology of Malignant LymphomasMolecular Cell Biology and Gene Therapy2004200620072020 Sort: Result score Newest to oldest Oldest to newest December 17, 2020 in Blood Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 S. Reinke P.J. Bröckelmann I. Iaccarino M. Garcia-Marquez S. Borchmann F. Jochims M. Kotrova K. Pal M. Brüggemann E. Hartmann S. Sasse C. Kobe S. Mathas M. Soekler U. Keller M. Bormann A. Zimmermann J. Richter M. Fuchs B. von Tresckow P. Borchmann H. Schlößer M. von Bergwelt-Baildon A. Rosenwald A. Engert W. Klapper June 01, 2020 in JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert October 01, 2007 in Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas May 01, 2007 in Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas March 01, 2007 in Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto November 01, 2006 in Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert July 01, 2006 in Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken May 15, 2006 in Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas March 15, 2006 in Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou February 01, 2006 in Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken Pagination Current page 1 Page 2 Next page Next › Last page Last »
December 17, 2020 in Blood Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 S. Reinke P.J. Bröckelmann I. Iaccarino M. Garcia-Marquez S. Borchmann F. Jochims M. Kotrova K. Pal M. Brüggemann E. Hartmann S. Sasse C. Kobe S. Mathas M. Soekler U. Keller M. Bormann A. Zimmermann J. Richter M. Fuchs B. von Tresckow P. Borchmann H. Schlößer M. von Bergwelt-Baildon A. Rosenwald A. Engert W. Klapper
June 01, 2020 in JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert
October 01, 2007 in Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas
May 01, 2007 in Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
March 01, 2007 in Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto
November 01, 2006 in Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
July 01, 2006 in Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
May 15, 2006 in Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
March 15, 2006 in Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
February 01, 2006 in Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken